New Hungary Pharma Report 2020 Out Now
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
Address: NYCOMED Pharma Kft., 1138 Budapest, Népfürdõ u. 22. (Duna Tower), Hungary,Hungary
Tel: +36 (1) 270-7030
Web: http://www.takedahungary.hu/hu/
Nycomed is a privately owned, global mid-sized pharmaceutical company with headquarters in Zurich, Switzerland. The company employs 12,500 associates worldwide and has affiliates in more than 70 countries, bringing medicines that matter to patients worldwide.
Nycomed has a strong presence in Europe and in fast-growing markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US and Japan its products are available through best-in-class partners.
The company has built a flexible business model around partnering to grow its R&D pipeline, its product portfolio, and extend its geographical reach.
Nycomed provides branded medicines for hospitals, specialists and general practitioners, as well as over-the-counter (OTC) medicines. Our strong global brands complement product portfolios adapted to local preferences. Around the world, our guiding principle is to develop “medicines that matter”.
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
Hungary’s longstanding tradition of pharmacology is a major point of pride for the country’s scientists and researchers who today have hopes to elevate the country’s research environment to a region-leading…
According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million…
Established in 1997, Medi-Radiopharma is a Hungarian privately held company operating in the field of nuclear medicine, a specialized area of radiology that uses very small amounts of radioactive materials,…
As general manager of the Hungarian affiliate of Swiss firm IBSA, Anna Wienner has proven herself to be a motivated pharma leader with particular expertise in reshaping and building organizations.…
Krisztina Kárpát, MD of Bayer Hungary, elaborates on the successful development of the affiliate in recent years, making progress in all three business units of pharma, consumer health, and crop…
Judit Bidlo, deputy director general of price support at the Hungarian National Health Insurance (NEAK), shares her insights on the healthcare system’s developments over the last three years, the rationale…
Among the efforts of Hungarian stakeholders to determine more efficient pricing and reimbursement structures, there is a common ambition to explore what is considered by many to be the next…
In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of…
Tamás Demeter, Country Manager for AOP Orphan shares his insights on the footprint of the company in Hungary, the areas of therapeutic need that AOP caters to, the performance of…
Katinka Zinnemers, managing director of Abacus Medicine, highlights the company’s mission to increase access to medicines for all patients and its commitment to building trust with authorities as it enters…
Csaba Kis, CEO of Qualiskills, shares his insights on the packaging capabilities of the company, its sustainable competitive advantage, the impact of the European serialization guidelines, and the company’s strategic…
See our Cookie Privacy Policy Here
